Article
AlphaMed Inc. announced that it received a $500,000 two-year STTR Phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.
Multicenter Study Sheds Light on Pediatric MMP
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD
Reviewing Complex Cases: Topicals for Pediatric AD
Atopic Dermatitis Insights on Global Prevalence, Health Care Implications, and the Impact of COVID-19
Daily Derm Times: April 2, 2025
Hand Eczema Prevalence and Patterns in East Greenland Similar to Nordic and European Trends